Healthcare / Drug Manufacturers - GeneralASX
$0.04
+0.00 (+7.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-2.3M · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-169.3%
↓Gross Margin
35.7%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+314.4%
FCF CAGR
—
FCF margin
-634.6%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $293422.0 · net income $-2.6M · FCF $-1.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $293422.00 | $293422.00 | $14522.00 | $830.00 | $4124.00 |
| Net Income | $-2.6M | $-2.6M | $-1.2M | $-6.8M | $-3.8M |
| EBITDA | $-2.9M | $-2.9M | $-1.2M | $-6.9M | $-3.8M |
| EPS | -0.01 | -0.01 | -0.01 | -0.04 | -0.03 |
| Gross Margin | 35.7% | 35.7% | -156.9% | 100.0% | 100.0% |
| Operating Margin | -976.6% | -976.6% | -27046.0% | -826956.4% | -118154.0% |
| Net Margin | -897.8% | -897.8% | -8097.1% | -819526.7% | -92054.1% |
| Balance Sheet | |||||
| Current Ratio | 6.32 | 6.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.9M | $-1.9M | $-2.3M | $-5.8M | $-4.2M |
| Returns | |||||
| ROE | -169.3% | -169.3% | -55.6% | -274.7% | -45.9% |
| Valuation | |||||
| P/B | 6.08 | 6.08 | 4.49 | 12.37 | 4.22 |
| Growth & Yield | |||||
| Revenue Growth | 1920.5% | 1920.5% | 1649.6% | -79.9% | — |
| EPS Growth | -89.4% | -89.4% | 83.5% | -22.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
-32.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.